Oxford Immunotec Raises $64 Million in Nasdaq Public Listing
This article is for subscribers only.
Oxford Immunotec Global Plc, a U.K. maker of a test for latent tuberculosis, raised $64.3 million in a U.S. initial public offering today, adding fuel to a rebound in listings this year among European biotechnology companies.
The company sold 5.36 million shares at $12 each after offering them for $13 to $15 apiece, Abingdon, England-based Oxford Immunotec said in an e-mailed statement today. The shares, listed on the Nasdaq Stock Market under the symbol OXFD, rose 28 percent to $15.40.